With neurological disorders contributing nearly 10% to India’s overall disease burden and ranking among the top causes of global disability, Gurugram-based Medanta – The Medicity is positioning its Deep Brain Stimulation (DBS) programme as a key growth driver in advanced neuro care.
Widely known as ‘Brain Pacemaker’ surgery, DBS has emerged as a high-value, technology-led intervention for advanced-stage Parkinson’s disease, dystonia, refractory epilepsy (adult onset), essential tremor and advanced obsessive-compulsive disorder (OCD). Medanta, named Best Private Hospital in India by Newsweek for six consecutive years, is recognised internationally as a destination centre for this therapy.
The programme is led by Dr. Anirban Deep Banerjee, Director, Neurosurgery, Institute of Neurosciences at Medanta Gurugram, who has performed over 300 DBS procedures in the past 15 years with consistently high success rates.
From a market standpoint, Medanta’s DBS offering integrates advanced imaging for precise brain targeting, directional leads for multi-dimensional neuromodulation, real-time brain-sensing biomarker feedback, AI-guided precision targeting and remote programming capabilities. The combination of cutting-edge technology and personalised care signals growing institutional investment in high-end neurostimulation therapies, as demand rises for specialised interventions when conventional medicines fail.
